AstraZeneca pays $19M to Harbour BioMed's Nona for preclinical cancer antibodies

Days after AstraZeneca set out how new oncology drugs would help fuel its “bold” ambition to almost double its revenue by the end of the decade, the Big Pharma has further swelled this pipeline via a deal with Harbour BioMed subsidiary Nona Biosciences.